Clinicopathological Features in Bilateral Breast Cancer

dc.contributor.authorBaykara, Meltem
dc.contributor.authorOzturk, Selcuk Cemil
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorHelvaci, Kaan
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorAlkis, Necati
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-04-24T17:28:16Z
dc.date.available2024-04-24T17:28:16Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction and Purpose: The frequency of bilateral breast cancer is 1.4-11.0% among all breast cancers. It can present as synchronous (SC) or metachronous (MC). Data regarding clinical course of bilateral breast cancer are scarce. In this study, we therefore evaluated demographic, pathological and clinical characteristics, treatments and responses in bilateral breast cancer cases; making distinctions between metachronous-synchronous and comparing with historic one-sided data for the same parameters. Materials and Methods: One hundred fifty bilateral breast cancer cases from ten different centers between 2000 and 2011 were retrospectively scanned. Age of the cases, family history, menopausal status, pathological features, pathological stages, neoadjuvant, surgery, adjuvant and palliative chemotherapy/radiotherapy were examined in the context of the first and second occurrence and discussed with reference to the literature. Results: Metachronous and synchronous groups showed similar age, menopausal status, tumor type, HER2/neu expression; the family history tumor grade, tumor stage, ER-negativity rate, local and distant metastases rates, surgery, adjuvant chemotherapy application rates were identified as significantly different. Palliative chemotherapy response rate was greater in the metachronous group but median PFS rates did not differ between the groups. Conclusion: Although bilateral breast cancer is not frequent, MC breast cancer is different from SC breast cancer by having more advanced grade, stage, less ER expression, more frequent rates of local relapse and distant metastasis and better response to chemotherapy in case of relapse/metastasis.en_US
dc.identifier.doi10.7314/APJCP.2012.13.9.4571
dc.identifier.endpage4575en_US
dc.identifier.issn1513-7368
dc.identifier.issue9en_US
dc.identifier.pmid23167382
dc.identifier.scopus2-s2.0-84874013941
dc.identifier.scopusqualityQ3
dc.identifier.startpage4571en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.9.4571
dc.identifier.urihttps://hdl.handle.net/11468/20385
dc.identifier.volume13en_US
dc.identifier.wosWOS:000312267800066
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBilateral Breast Canceren_US
dc.subjectSynchronousen_US
dc.subjectMetachronousen_US
dc.subjectClinicopathological Characteristicsen_US
dc.subjectTurkeyen_US
dc.titleClinicopathological Features in Bilateral Breast Canceren_US
dc.titleClinicopathological Features in Bilateral Breast Cancer
dc.typeArticleen_US

Dosyalar